10/18/2024

Janusmed sex and gender

Janusmed sex and gender – ticagrelor

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Ticagrelor

Ticagrelor

Class : A

Show all info

Print

Contact us

  1. Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012;51:305-18.

  2. Brilique (prasugrel). Summary of Product Charateristics. European Medicines Agency (EMA). [updated 2018-05-30, cited 2019-01-22].

  3. Brilinta (ticagrelor). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2019-01-22].

  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.

  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.

  6. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014;35(23):1541-50.

  7. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800.

  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]

  1. Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012;51:305-18.
  2. Brilique (prasugrel). Summary of Product Charateristics. European Medicines Agency (EMA). [updated 2018-05-30, cited 2019-01-22].
  3. Brilinta (ticagrelor). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2019-01-22].
  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.
  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.
  6. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014;35(23):1541-50.
  7. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800.
  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]